Serotonergic function in social phobia: Comparison to normal control and obsessive-compulsive disorder subjects

Psychiatry Research

Volumn 79, Issue 3, 1998, Pages 213-217

  Hollander, Eric ^a   Kwon, Jee ^a   Weiller, Fenia ^a   Cohen, Lisa ^a   Stein, Dan J ^a   DeCaria, Concetta ^a   Liebowitz, Michael ^a   Simeon, Daphne ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cortisol; m CPP; Obsessive compulsive disorder; Prolactin; Serotonin (5 HT); Social phobia

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; HYDROCORTISONE; PROLACTIN; SEROTONIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HYDROCORTISONE RELEASE; MALE; OBSESSION; PRIORITY JOURNAL; PROGNOSIS; PROLACTIN RELEASE; PROVOCATION TEST; SEROTONINERGIC NERVE CELL; SOCIAL PHOBIA;

EID: 0032514247     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(98)00041-9     Document Type: Article

References (21)

1. Bastani B., Nash J.F., Meltzer H.Y. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder. Archives of General Psychiatry. 47:1990;833-839.
2. Benkelfat C., Murphy D.L., Zohar J., Hill J.L., Grover G., Insel T.R. Clomipramine in obsessive-compulsive disorder: further evidence for serotonergic mechanism of action. Archives of General Psychiatry. 46:1989;23-28.
3. Black B., Uhde T.W., Tancer M.E. Fluoxetine for the treatment of social phobia (letter). Journal of Clinical Psychopharmacology. 12(4):1992;293-295.
4. Charney D.S., Woods S.W., Krystal J.H., Heninger G.R. Serotonin function and human anxiety disorders. Annals of the New York Academy of Science. 600:1990;558-573.
5. Geller I., Blum K. The effects of 5-HTP on parachlorophenylalanine (p-CPA) attenuation of 'conflict' behavior. European Journal of Pharmacology. 9:1970;319-324.
6. Hollander E., DeCaria C., Gulley R., Nitescu A., Suchow R.F., Gorman J.G., Klein D.F., Liebowitz M.R. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine response to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Research. 36:1991;1-17.
7. Hollander E., DeCaria C., Nitescu A., Gully R., Suckow R.F., Cooper T.B., Gorman J.M., Klein D.F., Liebowitz M.R. Serotonergic function in OCD: behavioral and neuroendocrine responses to oral m-CPP and fenfluramine in patients and healthy volunteers. Archives of General Psychiatry. 49:1992;21-28.
8. Liebowitz M.R., Gorman J.M., Fyer A.J., Campeas R., Levin A.P., Sandberg D., Hollander E., Papp L., Goetz D. Pharmacotherapy of social phobia: an interim report of a placebo controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry. 49:1988;252-257.
9. Liebowitz M.R., Gorman J.M., Fyer A.J., Klein D.F. Social phobia: review of neglected anxiety disorder. Archives of General Psychiatry. 42:1985;729-736.
10. Liebowitz M.R., Fyer A.J., Gorman J.M., Dillon D., Davies S., Stein J.M., Cohen B.S., Klein D.F. Specificity of lactate infusions in social phobia versus panic disorders. American Journal of Psychiatry. 142:1985;947-950.
11. Lydiard R.B., Laraia M.T., Howell E.F. Alprazolam in the treatment of social phobia. Journal of Clinical Psychiatry. 49:1988;17-19.
12. Munjack D.J., Bruns J., Baltazar P.L., Brown R., Leonard M., Nagy R., Koek R., Crocker B., Schafer S. A pilot study of buspirone in the treatment of social phobia. Journal of Anxiety Disorders. 5:1991;87-98.
13. Papp L.A., Gorman J.M., Liebowitz M.R., Fyer A.J., Cohen B., Klein D.F. Epinephrine infusions in patients with social phobia. American Journal of Psychiatry. 145(6):1988;733-736.
14. Pigott T.A., Zohar J., Hill J.L., Bernstein S.E., Grover G.N., Zohar-Kadouch R.C., Murphy D.L. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-CPP in patients with OCD. Biological Psychiatry. 29:1991;418-426.
15. Reiter S.R., Pollack M.H., Rosenbaum J.F. Clonazepam for the treatment of social phobia. Journal of Clinical Psychiatry. 51:1990;470-472.
16. Schneier F.R., Johnson J., Hornig C.D., Liebowitz M.R., Weissman M. Social phobia comorbidity and morbidity in an epidemiologic sample. Archives of General Psychiatry. 49:1992;282-288.
17. Schneier F.R., Saoud J.B., Campeas R., Fallon B.A., Hollander E., Coplan J., Liebowitz M.R. Buspirone in social phobia. Journal of Clinical Psychopharmacology. 13:1993;251-256.
18. Tancer M.E., Mailman R.B., Stein M.B., Mason G.A., Carson S.W., Golden R.N. Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia. Anxiety. 1((5)):1995;216-223.
19. Van Ameringen M., Mancini C., Streiner D.L. Fluoxetine efficacy in social phobia. Journal of Clinical Psychopharmacology. 54(1):1993;27-32.
20. Versiani M., Mundim D.F., Nardi A.E., Liebowitz M.R. Tranylcypromine in social phobia. Journal of Clinical Psychopharmacology. 8:1988;279-283.
21. Zohar J., Mueller E.A., Insel T.R., Zohar-Kadouch R.C., Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Archives of General Psychiatry. 44:1987;946-951.